NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT00948961 2016-06-27A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1Celldex TherapeuticsPhase 1/2 Completed70 enrolled